Clarethis SRL
Clarethis reported total assets of 172,781 € at the end of the 2025 financial year (annual accounts filed with the NBB on 07 May 2026).
The score of Clarethis shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2025
Change 2022 → 2025: Equity +1116 % Total assets +4 %
Accounts of the company itself (not consolidated).
The full file covers 10 financial years; a free account shows 2. →Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error
Clarethis's annual accounts
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net result | −27,994 € | ||||
| Equity | 85,683 € | ||||
| Cash | 31,489 € | ||||
| EBITDA | 62,583 € | ||||
| Total assets | 172,781 € |
Filed annual accounts
- Year ended 30 Sep 2025filed on 07 May 2026
- Year ended 30 Sep 2024filed on 29 Apr 2025
- Year ended 30 Sep 2023filed on 30 Apr 2024
- Year ended 30 Sep 2022filed on 03 May 2023
- Year ended 30 Sep 2021filed on 16 May 2022
Clarethis's financial analysis
- Solvency49.6%sector median: 38.7%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of Clarethis
Clarethis's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 0894.880.626
- VAT number
- BE0894880626
- Peppol
- Registered · 0208:0894880626 · as of 10 Nov 2026
- Legal form
- SRL
- Incorporated
- 08 Jan 2008
- Registered office
- 7061 Soignies
- Latest accounts
- 2025 · filed on 07 May 2026
- Activity
- Manufacture of basic pharmaceutical products (NACE 21100)
Clarethis (SRL) has been based in Soignies since 2008, active in: manufacture of basic pharmaceutical products. For 2025, it reports a net loss of 27,994 € and equity of 85,683 €; its revenue is not published. Its solvency stands at 49.6%, above the median of its sector (38.7%).
Guide: Reading Belgian SME accounts: the five figures that count →
Companies similar to Clarethis
Companies in the same business, of comparable size and area, outside its group.
- Laboratoire DIPO Manufacture of perfume and toilet preparations Etterbeek · balance sheet 24,259 €
- Pharmacie Courouble Manufacture of basic pharmaceutical products Schaerbeek · balance sheet 129,672 €
- Vesale Pharma Woman Health Wholesale of pharmaceutical and medical goods Éghezée · balance sheet 62,158 €
- Pharma Leyens Retail sale of pharmaceutical products Liège · balance sheet 311,356 €
- Human Pharma Retail sale of pharmaceutical products Charleroi · balance sheet 434,132 €
- Apego Retail sale of pharmaceutical products Geel · balance sheet 89,749 €
- Asterion Therapeutics Manufacture of pharmaceutical preparations Beveren-Kruibeke-Zwijndrecht · balance sheet 58,464 €
- Apotheek Debackere Leen Retail sale of pharmaceutical products Aalter · balance sheet 354,864 €
Frequently asked questions about Clarethis
What is the revenue of Clarethis?
Clarethis files its accounts in a format where revenue is optional: it is not published for 2025.
What is the VAT number of Clarethis?
In Belgium, the VAT number is the company number prefixed with BE: BE0894880626 for Clarethis, if the company is VAT-registered. Its company number (CBE) is 0894.880.626.
Where is the registered office of Clarethis?
According to the CBE register, the registered office of Clarethis is in 7061 Soignies.
What is the equity of Clarethis?
At the close of the 2025 financial year, the equity of Clarethis amounts to 85,683 €, a solvency of 49.6% of total assets.
Who manages Clarethis?
The register lists 1 active mandates at Clarethis. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
The full file of Clarethis
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →